Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[KRP-297, MCC-555].

T Yamanouchi1

  • 1Department of Internal Medicine, University of Teikyo.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Two novel thiazolidinediones, KRP-297 and MCC-555, show promise for treating diabetes by activating peroxisome proliferator-activated receptors (PPAR). KRP-297 uniquely targets both PPAR alpha and gamma, improving glucose and lipid levels in diabetic models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A mechanical coil insertion system for endovascular coil embolization of intracranial aneurysms.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2013
Same author

An algebraic description of painted digital pictures.

IEEE transactions on pattern analysis and machine intelligence·2012
Same author

Esophageal atresia with double tracheoesophageal fistula--a case report and review of the literature.

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie·2005
Same author

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2005
Same author

Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.

Diabetes, obesity & metabolism·2003
Same author

Effects of omega-3 fatty acids in rat allogenic small intestinal transplantation.

Pediatric surgery international·2003
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Thiazolidinediones are a class of drugs used to treat type 2 diabetes.
  • Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that play a role in glucose and lipid metabolism.
  • KRP-297 and MCC-555 are novel thiazolidinediones developed in Japan.

Purpose of the Study:

  • To investigate the unique binding and activation properties of KRP-297 and MCC-555 on PPARs.
  • To evaluate the effects of KRP-297 on glucose uptake and metabolic parameters in diabetic animal models.
  • To characterize MCC-555's activity as a PPAR gamma modulator.

Main Methods:

  • In vitro binding assays to determine PPAR receptor affinity.
  • In vivo studies using diabetic animal models to assess antidiabetic effects.

Related Experiment Videos

  • Measurement of plasma glucose, insulin, triglyceride, and free fatty acid levels.

    • Main Results:

    • KRP-297 demonstrated unique dual activation of PPAR gamma and PPAR alpha.
    • KRP-297 directly enhanced basal glucose uptake in rat skeletal muscle.
    • KRP-297 reduced plasma glucose, insulin, triglyceride, and free fatty acid levels in diabetic models.
    • MCC-555 exhibited significant antidiabetic properties and acts as a PPAR gamma modulator.

    Conclusions:

    • KRP-297 and MCC-555 represent novel therapeutic agents for diabetes with distinct PPAR activation profiles.
    • KRP-297's dual PPAR agonism and direct effect on glucose uptake suggest broad metabolic benefits.
    • Further clinical evaluation is warranted for these promising antidiabetic compounds.